The prices of essential drugs and lifesaving medicines are set to increase by over 12% from the beginning of the coming month. This hike will encompass 384 essential drugs in the National List of Essential Medicines (NLEM).
These drugs include – analgesics, antibiotics, and cardiac medicine. Recently, the National Pharmaceutical Pricing Authority (NPPA) announced that the price rise is occurring due to wholesale price inflation – based on the provisions of the DPCO (Drugs Price Control Order). In comparison, the last year’s change in WPI was 10.7%, while the 2021 WPI increase was 0.53%.
Further, the prices of 25 drugs have been fixed – as per the DPCO, 2013. These include - Camylofin Dihydrochloride and Paracetamol tablets – ₹5.53, and Itraconazole capsules – ₹20.72.
The fixing of prices is to affect over 800 essential medicines and medical devices.
Pharmaceutical companies will be issuing the altered prices through Form-V. These companies include – Abbott, Alembic, Aristo-Pharma, Cipla, Glenmark Pharma, Lupin, Mankind, Sun Pharma, Torrent, Wockhardt, and Zydus Healthcare, among others.
Of note, this is the second year in a row that the price rise of scheduled drugs will be higher than non-scheduled drugs.
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article